Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study.
Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been...
Read More